Guido Ferrari, MD is an Associate Professor at Duke University in the Department of Surgery and Molecular Genetics and Microbiology. He is also affiliated as faculty at the Duke Global Health Institute, Duke Human Vaccine Institute, and University of Cape Town Department of Immunology. Since 1995 Dr. Ferrari has been testing samples from vaccine recipients for cytotoxic T lymphocyte (CTL) and antibody-dependent cellular cytotoxic (ADCC) responses for the HIV Vaccine Trial Network (HVTN) where he is currently Director of the ADCC Laboratory. Dr. Ferrari has also been the Director of the ADCC core laboratory for the Comprehensive Antibody-Vaccine Immune Monitoring Consortium (CA-VIMC) and for the Primate AIDS Vaccine Evaluation Group (PAVEG). He was the first to characterize vaccine-induced cross-clade clade CD8 CTL responses and the difference in class I-restricted epitope recognition between individuals with HIV-1 infection and vaccine recipients. He followed this initial epitope mapping of cellular responses with epitope mapping of ADCC responses to identify the anti-C1C2 epitope as the most recognized epitope by ADCC Ab responses in individuals with HIV. Dr. Ferrari has organised 10 symposia to strengthen collaborations among more than 300 young African scientists in collaboration with Professor Clive Gray at the University of Cape Town.